CL2018000226A1 - Mezcla de péptidos (divisional solicitud 201601405) - Google Patents
Mezcla de péptidos (divisional solicitud 201601405)Info
- Publication number
- CL2018000226A1 CL2018000226A1 CL2018000226A CL2018000226A CL2018000226A1 CL 2018000226 A1 CL2018000226 A1 CL 2018000226A1 CL 2018000226 A CL2018000226 A CL 2018000226A CL 2018000226 A CL2018000226 A CL 2018000226A CL 2018000226 A1 CL2018000226 A1 CL 2018000226A1
- Authority
- CL
- Chile
- Prior art keywords
- peptide mixture
- divisional application
- peptides
- ras protein
- understand
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000016914 ras Proteins Human genes 0.000 abstract 2
- 108010014186 ras Proteins Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras, Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
Abstract
<p>SE DESCRIBE UNA MEZCLA DE PÉPTIDOS ADECUADA PARA PRODUCIR UNA RESPUESTA INMUNITARIA. COMPRENDE PÉPTIDOS, CADA UNO QUE CORRESPONDE A UN FRAGMENTO DE LA PROTEÍNA RAS. CADA UNO LOS PÉPTIDOS COMPRENDE UNA REGIÓN DE AL MENOS 6 O AL MENOS 8 AMINOÁCIDOS QUE INCLUYE LA POSICIÓN 12 DE LA PROTEÍNA RAS.</p>
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13196333 | 2013-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000226A1 true CL2018000226A1 (es) | 2018-06-22 |
Family
ID=49765823
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001405A CL2016001405A1 (es) | 2013-12-09 | 2016-06-08 | A peptide mixture |
| CL2018000238A CL2018000238A1 (es) | 2013-12-09 | 2018-01-26 | Mezcla de péptidos (divisional solicitud 201601405) |
| CL2018000232A CL2018000232A1 (es) | 2013-12-09 | 2018-01-26 | Mezcla de péptidos (divisional solicitud 201601405) |
| CL2018000226A CL2018000226A1 (es) | 2013-12-09 | 2018-01-26 | Mezcla de péptidos (divisional solicitud 201601405) |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001405A CL2016001405A1 (es) | 2013-12-09 | 2016-06-08 | A peptide mixture |
| CL2018000238A CL2018000238A1 (es) | 2013-12-09 | 2018-01-26 | Mezcla de péptidos (divisional solicitud 201601405) |
| CL2018000232A CL2018000232A1 (es) | 2013-12-09 | 2018-01-26 | Mezcla de péptidos (divisional solicitud 201601405) |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US9775892B2 (es) |
| EP (5) | EP3363458A3 (es) |
| JP (2) | JP6781403B2 (es) |
| KR (1) | KR20160097290A (es) |
| CN (1) | CN105980403A (es) |
| AU (2) | AU2014363643B2 (es) |
| BR (1) | BR112016013138A2 (es) |
| CA (1) | CA2933126A1 (es) |
| CL (4) | CL2016001405A1 (es) |
| CY (1) | CY1120578T1 (es) |
| DK (1) | DK3079715T3 (es) |
| ES (1) | ES2682038T3 (es) |
| HR (1) | HRP20181213T1 (es) |
| HU (1) | HUE039840T2 (es) |
| IL (1) | IL246007D0 (es) |
| LT (1) | LT3079715T (es) |
| MX (1) | MX2016007429A (es) |
| PL (1) | PL3079715T3 (es) |
| PT (1) | PT3079715T (es) |
| RS (1) | RS57623B1 (es) |
| RU (1) | RU2016127327A (es) |
| SG (2) | SG11201604644QA (es) |
| SI (1) | SI3079715T1 (es) |
| WO (1) | WO2015086590A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201604644QA (en) | 2013-12-09 | 2016-07-28 | Targovax Asa | A peptide mixture |
| DK3140320T3 (en) | 2014-05-06 | 2019-04-15 | Targovax Asa | PEPTID VACCINE CONTAINING MUTANT RACE PEPTID AND CHEMOTHERAPEUTIC AGENTS |
| CN110430894A (zh) * | 2017-02-01 | 2019-11-08 | 莫得纳特斯公司 | 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物 |
| AU2018288386A1 (en) * | 2017-06-22 | 2020-02-06 | New South Wales Health Pathology | Adoptive T cell therapy 2 |
| CN112638404A (zh) * | 2018-06-19 | 2021-04-09 | 百欧恩泰美国公司 | 新抗原及其用途 |
| WO2020002650A1 (en) | 2018-06-29 | 2020-01-02 | Targovax Asa | A formulation |
| AU2019324162A1 (en) * | 2018-08-22 | 2021-03-04 | Fred Hutchinson Cancer Center | Immunotherapy targeting KRAS or Her2 antigens |
| WO2021009633A1 (en) * | 2019-07-12 | 2021-01-21 | Massey University | Synthetic chromatin vaccine |
| WO2021087840A1 (zh) * | 2019-11-07 | 2021-05-14 | 武汉华大吉诺因生物科技有限公司 | 肿瘤免疫治疗多肽及其应用 |
| CN113416241B (zh) * | 2020-04-09 | 2022-04-08 | 北京臻知医学科技有限责任公司 | 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103974D0 (en) | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| GB2328689A (en) * | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| KR101164509B1 (ko) | 2002-12-16 | 2012-07-10 | 글로브이뮨 | 면역 요법으로서의 효모계 백신 |
| DE602005016112D1 (de) | 2005-09-05 | 2009-10-01 | Immatics Biotechnologies Gmbh | Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe |
| US7745128B2 (en) * | 2006-03-27 | 2010-06-29 | Globeimmune, Inc. | Ras mutation and compositions and methods related thereto |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| SG11201604644QA (en) | 2013-12-09 | 2016-07-28 | Targovax Asa | A peptide mixture |
| DK3140320T3 (en) | 2014-05-06 | 2019-04-15 | Targovax Asa | PEPTID VACCINE CONTAINING MUTANT RACE PEPTID AND CHEMOTHERAPEUTIC AGENTS |
-
2014
- 2014-12-09 SG SG11201604644QA patent/SG11201604644QA/en unknown
- 2014-12-09 WO PCT/EP2014/077033 patent/WO2015086590A2/en active Application Filing
- 2014-12-09 PL PL14828148T patent/PL3079715T3/pl unknown
- 2014-12-09 SG SG10201811172PA patent/SG10201811172PA/en unknown
- 2014-12-09 EP EP18166281.8A patent/EP3363458A3/en not_active Withdrawn
- 2014-12-09 EP EP18166278.4A patent/EP3369432A1/en active Pending
- 2014-12-09 AU AU2014363643A patent/AU2014363643B2/en active Active
- 2014-12-09 CA CA2933126A patent/CA2933126A1/en not_active Abandoned
- 2014-12-09 BR BR112016013138-0A patent/BR112016013138A2/pt not_active Application Discontinuation
- 2014-12-09 EP EP14828148.8A patent/EP3079715B1/en active Active
- 2014-12-09 PT PT148281488T patent/PT3079715T/pt unknown
- 2014-12-09 SI SI201430776T patent/SI3079715T1/en unknown
- 2014-12-09 EP EP18166279.2A patent/EP3363457A1/en active Pending
- 2014-12-09 EP EP18164079.8A patent/EP3357505A1/en active Pending
- 2014-12-09 DK DK14828148.8T patent/DK3079715T3/en active
- 2014-12-09 CN CN201480074531.3A patent/CN105980403A/zh active Pending
- 2014-12-09 LT LTEP14828148.8T patent/LT3079715T/lt unknown
- 2014-12-09 US US15/102,681 patent/US9775892B2/en active Active
- 2014-12-09 RS RS20180907A patent/RS57623B1/sr unknown
- 2014-12-09 HU HUE14828148A patent/HUE039840T2/hu unknown
- 2014-12-09 JP JP2016557194A patent/JP6781403B2/ja active Active
- 2014-12-09 KR KR1020167018341A patent/KR20160097290A/ko not_active Application Discontinuation
- 2014-12-09 RU RU2016127327A patent/RU2016127327A/ru not_active Application Discontinuation
- 2014-12-09 MX MX2016007429A patent/MX2016007429A/es unknown
- 2014-12-09 ES ES14828148.8T patent/ES2682038T3/es active Active
-
2016
- 2016-06-02 IL IL246007A patent/IL246007D0/en unknown
- 2016-06-08 CL CL2016001405A patent/CL2016001405A1/es unknown
-
2017
- 2017-03-17 US US15/461,837 patent/US10335473B2/en active Active
- 2017-08-02 US US15/667,288 patent/US10456457B2/en active Active
- 2017-09-27 US US15/716,861 patent/US10596239B2/en active Active
-
2018
- 2018-01-26 CL CL2018000238A patent/CL2018000238A1/es unknown
- 2018-01-26 CL CL2018000232A patent/CL2018000232A1/es unknown
- 2018-01-26 CL CL2018000226A patent/CL2018000226A1/es unknown
- 2018-07-30 HR HRP20181213TT patent/HRP20181213T1/hr unknown
- 2018-08-10 CY CY20181100846T patent/CY1120578T1/el unknown
-
2019
- 2019-03-20 AU AU2019201937A patent/AU2019201937B2/en active Active
- 2019-10-04 JP JP2019183442A patent/JP2020023525A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000226A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| CL2019003657A1 (es) | Anticuerpos que se unen específicamente a cd38 útiles para mejorar una respuesta inmune en un paciente. (divisional solicitud 201703275) | |
| CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
| BR112018011073A2 (pt) | anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização | |
| EA201690333A1 (ru) | МОДУЛОКИНЫ НА ОСНОВЕ ДОМЕНА SUSHI IL-15 И IL-15Rα | |
| UY33983A (es) | Proteínas de Unión de Tipo Anticuerpo con Región Variable Dual que Tienen Orientación de la Región de Unión con Entrecruzamiento. | |
| CL2017003228A1 (es) | Fragmentos mutantes de proteína ras | |
| CL2017001610A1 (es) | Anticuerpos humanos para hemagglutinina de influenza | |
| BR112015009924A2 (pt) | formulações de proteína imunoglobulina de domínio variável duplo estáveis | |
| BR112017008165A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
| CU20190058A7 (es) | Composiciones de aminoácidos relacionadas con mejoras de la función hepática | |
| BR112018074468A2 (pt) | anticorpos anti-cd40 e suas utilizações | |
| EA201591931A1 (ru) | Композиции оксабициклогептанов и оксабициклогептенов | |
| BR112018075032A2 (pt) | proteínas de hemaglutinina do vírus influenza e seus uso | |
| BR112016024494A8 (pt) | análogo de peptídeo e seu uso | |
| BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
| BR112016022844A2 (pt) | método para aperfeiçoar a solubilidade de proteínas e peptídeos utilizando-se uma ligação de fragmento fc de imunoglobulinas | |
| BR112015025699A2 (pt) | modulação de especificidade de polipeptídeo estruturado | |
| DK3146042T3 (da) | Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop | |
| BR112016013157A2 (pt) | peptídeos resistentes à protease | |
| UA117493C2 (uk) | Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання | |
| CL2019003167A1 (es) | Proteínas de unión al antígeno anti-jagged1. | |
| BR112015032388A2 (pt) | métodos e composições para as vacinas contra o vírus da dengue | |
| BR112012013581A2 (pt) | vacinas de malária baseadas em ferlinas apicomplexas, proteínas semelhante a ferlinas e outras proteínas que contêm o domínio c2 | |
| MX2019007924A (es) | Vacunas contra la influenza. |